[HTML][HTML] Multi-gene panel testing increases germline predisposing mutations' detection in a cohort of breast/ovarian cancer patients from Southern Italy
M Nunziato, F Di Maggio, M Pensabene… - Frontiers in …, 2022 - frontiersin.org
Breast cancer is the most common neoplasia in females worldwide, about 10% being
hereditary/familial and due to DNA variants in cancer-predisposing genes, such as the …
hereditary/familial and due to DNA variants in cancer-predisposing genes, such as the …
[HTML][HTML] Clinical usefulness of NGS multi-gene panel testing in hereditary cancer analysis
F Anaclerio, L Pilenzi, A Dell'Elice, R Ferrante… - Frontiers in …, 2023 - frontiersin.org
Introduction: A considerable number of families with pedigrees suggestive of a Mendelian
form of Breast Cancer (BC), Ovarian Cancer (OC), or Pancreatic Cancer (PC) do not show …
form of Breast Cancer (BC), Ovarian Cancer (OC), or Pancreatic Cancer (PC) do not show …
[HTML][HTML] NGS Panel Testing of Triple-Negative Breast Cancer Patients in Cyprus: A Study of BRCA-Negative Cases
M Zanti, MA Loizidou, K Michailidou, P Pirpa… - Cancers, 2020 - mdpi.com
Simple Summary In Cyprus, approximately 9% of triple-negative (negative in common breast
cancer receptors—estrogen, progesterone, and human epidermal growth factor receptor 2 …
cancer receptors—estrogen, progesterone, and human epidermal growth factor receptor 2 …
[HTML][HTML] Identification of the most common BRCA alterations through analysis of germline mutation databases: is droplet digital PCR an additional strategy for the …
A Lavoro, A Scalisi, S Candido… - International …, 2022 - spandidos-publications.com
Breast and ovarian cancer represent two of the most common tumor types in females
worldwide. Over the years, several non‑modifiable and modifiable risk factors have been …
worldwide. Over the years, several non‑modifiable and modifiable risk factors have been …
[HTML][HTML] Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population
IG Goidescu, G Caracostea, DT Eniu… - Clujul Medical, 2018 - ncbi.nlm.nih.gov
Prevalence of deleterious mutations among patients with breast cancer referred for multigene
panel testing in a Romanian population - PMC Back to Top Skip to main content NIH NLM …
panel testing in a Romanian population - PMC Back to Top Skip to main content NIH NLM …
Validation of an NGS approach for diagnostic BRCA1/BRCA2 mutation testing
D Dacheva, R Dodova, I Popov, T Goranova… - Molecular diagnosis & …, 2015 - Springer
Abstract Background and Objective Pathogenic mutations in BRCA1/2 tumor suppressor
genes increase the lifetime risk for developing breast and ovarian cancer. The aim of the …
genes increase the lifetime risk for developing breast and ovarian cancer. The aim of the …
Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations
J Singh, N Thota, S Singh, S Padhi, P Mohan… - Breast cancer research …, 2018 - Springer
Purpose Breast and/or ovarian cancers are among the most common cancers in women
across the world. In the Indian population, the healthcare burden of breast and/or ovarian …
across the world. In the Indian population, the healthcare burden of breast and/or ovarian …
Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics
L Moreno, C Linossi, I Esteban, N Gadea… - Clinical and …, 2016 - Springer
Purpose Originally, BRCA testing was used for risk assessment and prevention strategies for
breast and ovarian cancer. Nowadays, BRCA status may influence therapeutic decision …
breast and ovarian cancer. Nowadays, BRCA status may influence therapeutic decision …
[HTML][HTML] BRCA1 and BRCA2 Testing through Next Generation Sequencing in a Small Cohort of Italian Breast/Ovarian Cancer Patients: Novel Pathogenic and …
P Concolino, G Gelli, R Rizza, A Costella… - International Journal of …, 2019 - mdpi.com
The aim of this report is to describe results of BRCA1 and BRCA2 Next Generation
Sequencing Analysis (NGS) analysis in 132 selected Italian patients with breast/ovarian …
Sequencing Analysis (NGS) analysis in 132 selected Italian patients with breast/ovarian …
Optimizing the identification of risk‐relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families
The introduction of multigene panel testing for hereditary breast/ovarian cancer screening
has greatly improved efficiency, speed, and costs. However, its clinical utility is still debated …
has greatly improved efficiency, speed, and costs. However, its clinical utility is still debated …